Developmental Programming of Renal Function and Re-Programming Approaches

Eva Nüsken, Jörg Dötsch, Lutz T. Weber and Kai-Dietrich Nüsken*

Pediatric Nephrology, Department of Pediatrics, Medical Faculty, University of Cologne, Cologne, Germany

Chronic kidney disease affects more than 10% of the population. Programming studies have examined the interrelationship between environmental factors in early life and differences in morbidity and mortality between individuals. A number of important principles has been identified, namely permanent structural modifications of organs and cells, long-lasting adjustments of endocrine regulatory circuits, as well as altered gene transcription. Risk factors include intrauterine deficiencies by disturbed placental function or maternal malnutrition, prematurity, intrauterine and postnatal stress, intrauterine and postnatal overnutrition, as well as dietary dysbalances in postnatal life. This mini-review discusses critical developmental periods and long-term sequelae of renal programming in humans and presents studies examining the underlying mechanisms as well as interventional approaches to “re-program” renal susceptibility toward disease. Clinical manifestations of programmed kidney disease include arterial hypertension, proteinuria, aggravation of inflammatory glomerular disease, and loss of kidney function. Nephron number, regulation of the renin–angiotensin–aldosterone system, renal sodium transport, vasomotor and endothelial function, myogenic response, and tubuloglomerular feedback have been identified as being vulnerable to environmental factors. Oxidative stress levels, metabolic pathways, including insulin, leptin, steroids, and arachidonic acid, DNA methylation, and histone configuration may be significantly altered by adverse environmental conditions. Studies on re-programming interventions focused on dietary or anti-oxidative approaches so far. Further studies that broaden our understanding of renal programming mechanisms are needed to ultimately develop preventive strategies. Targeted re-programming interventions in animal models focusing on known mechanisms will contribute to new concepts which finally will have to be translated to human application. Early nutritional concepts with specific modifications in macro- or micronutrients are among the most promising approaches to improve future renal health.

Keywords: kidney development, nephron number, renin–angiotensin–aldosterone system, renal sodium transport, blood pressure, early nutrition, re-programming intervention

INTRODUCTION

Prevention of chronic kidney disease is a major public health challenge (1). Although diabetes mellitus is the most common cause of chronic kidney disease worldwide (2), developmental programming processes that have been reviewed by us (3, 4) and others (5–7) before substantially contribute to differences in morbidity and mortality between individuals. The normal development of the kidney
can be disturbed by multiple environmental factors, including intrauterine deficiencies by disturbed placental function or maternal malnutrition, prematurity, intrauterine and postnatal stress, intrauterine and postnatal overnutrition, as well as dietary dysbalances of macro- and micronutrients. Since developmental steps take place during unique developmental periods, timing, and duration of an adverse environment specifically impact on developmental programming. Adverse kidney programming increases the incidence of severe renal and cardiovascular sequels later in life. This includes arterial hypertension and associated end organ damage, the aggravation of inflammatory glomerular disease and the occurrence of end-stage renal disease. Specific “re-programming” interventions may mitigate or even prevent programmed disease. Consequently, our mini-review will address the following topics:

(1) Which developmental stages are especially vulnerable?
(2) What are the long-term sequelae of adverse renal programming?
(3) Which environmental factors may have impact on kidney development and what are potential mechanisms of developmental kidney programming?
(4) What are potential therapeutic “re-programming” interventions?

CRITICAL DEVELOPMENTAL PERIODS OF RE-NAL PROGRAMMING IN HUMANS

In humans the pronephros begins to form around day 22, urine production starts after 10 weeks (8), and maximum renal growth occurs between 26 and 34 weeks of gestation (9). Around week 36, nephrogenesis is completed and the number of nephrons is determined (8, 10). In preterm infants, adaptation to extrauterine conditions impairs nephrogenesis, and the children end up with fewer nephrons and a higher percentage of morphologically abnormal glomeruli (5, 6, 11, 12). In small for gestational age (SGA) fetuses, intrauterine renal growth is reduced compared to appropriate for gestational age controls (9). In both term and preterm infants, glomerular and tubular functions undergo further maturation changes during the first months of life (8, 13). In these vulnerable periods, babies are often exposed to nephrotoxic medication, such as non-steroidal anti-inflammatory drugs (14), antibiotics, or diuretics, during neonatal intensive care unit treatment (15, 16).

LONG-TERM SEQUELAE OF RE-NAL PROGRAMMING IN HUMANS

Blood Pressure and Loss of Kidney Function

Hypertension is the most important risk factor for cardiovascular events and mortality worldwide (17). Elevated blood pressure contributes to progression of renal insufficiency (18) and is a strong independent risk factor for end-stage renal disease (19). *Vice versa*, decreased renal function is associated with increased blood pressure and cardiovascular morbidity (20). Early detection of blood pressure elevation plays a major role in the prevention of end organ damage (21). Many studies, including a systematic meta-analysis of studies tracking blood pressure during life course, demonstrated that childhood blood pressure predicts blood pressure (22–24) and vascular end organ damage in adulthood (25). Abnormal birth weight, either low or high, increases the risk for blood pressure elevation and loss of renal function in a U-shaped manner (26–31). In SGA individuals, some studies demonstrated elevated blood pressure in childhood (32) or adulthood (33, 34) especially when rapid postnatal catch-up growth and later adiposity were present (35). Further risk factors include high maternal BMI (36) or elevated protein/carbohydrate ratios in maternal diet during pregnancy (37, 38), rapid postnatal weight gain (39), or being born large for gestational age (36, 40, 41).

Proteinuria and Loss of Kidney Function

Several risk factors during early life predispose toward proteinuria and related decline of renal function. Accordingly, the prevalence of microalbuminuria among adults whose mothers had been exposed to the Dutch Hunger Winter 1944/45 was elevated (42). Chinese women born in the famine years 1959–1961 had a higher risk to develop more severe stages of proteinuria in their forties (43). Low birthweight itself is associated with elevated risks for albuminuria (OR, 1.81; 95% CI, 1.19–2.77), end-stage renal disease (OR, 1.58; 95% CI, 1.33–1.88), or low estimated glomerular filtration rate (GFR) (29, 44, 45). A birthweight-dependent decline in GFR may already be seen in childhood (29, 46, 47).

Glomerular Disease and Inflammation

Furthermore, a number of studies have evaluated the association between perinatal risk factors and later glomerular disease. Thus, SGA individuals have a higher risk to experience steroid resistance and a more severe course in nephrotic syndrome (48, 49). In IgA-nephropathy, they develop arterial hypertension and glomerulosclerosis more often (50).

MECHANISMS OF RE-NAL PROGRAMMING

In human studies, it is difficult to establish mechanistic links in the field of developmental programming since there usually is a large delay between an adverse event and the related clinical phenotype. This makes it very challenging to distinguish the underlying causes from multiple modifying factors. Thus, animal models providing the possibility of equalized postnatal conditions and specific interventions are especially valuable. In rodents, kidney development during the early postnatal period corresponds to the third trimester in humans (10). For an overview of mechanisms see Figure 1.

Nephron Number

Nephron number in humans ranges from ~200,000 to >2.5 million nephrons per kidney (51). The well-known hypothesis of Brenner et al. linked decreased glomerular number with increased glomerular size, hyperfiltration, hypertension, and progressive glomerular injury (7, 52). Nephron number positively correlates with birth weight (53, 54) and is reduced after low-protein (LP) diet throughout pregnancy (55–59), utero-placental insufficiency
(60–62), intrauterine glucocorticoid exposure (63), preterm birth (11, 64), and oxidative stress (65). In addition, a diet deficient in vitamin A (58, 66), zinc (67), or iron (68) is associated with low nephron count. Finally, nephrons get lost with age (69). Interestingly, low nephron number in young individuals is not necessarily associated with hypertension (70, 71). Thus, modulating factors such as early hyperalimentation and aging processes certainly have an impact on renal outcome in individuals with low nephron count (71, 72).

**Renin–Angiotensin–Aldosterone System (RAAS)**

Dysregulation of all or single components of the RAAS system may severely impair renal development (73, 74). Both activating and deactivating effects on the RAAS can induce a vicious circle of persisting hormonal dysbalances which may finally contribute to the development of arterial hypertension and renal failure.

In the fetal and perinatal period, downregulation of the RAAS has been identified as a relevant mechanism. In neonatal rats after LP diet during gestation, renal renin and angiotensin II levels (75) as well as angiotensin II receptors type 1 (AT1R) and 2 (AT2R) protein expressions (76) were reduced. Similarly, renal AT2R gene and protein expressions were reduced in fetal rats after prenatal caffeine exposure (77). Fetal angiotensin II levels in plasma were decreased after maternal high-salt diet in sheep (78).

Later in life, most environmental influences during early childhood end up with a RAAS activation. Adult rat offspring from the LP diet model showed elevated blood pressure (59), increased AT1R expression (79, 80) and elevated plasma angiotensin–converting enzyme (ACE) activity going along with slightly elevated angiotensin II levels (81). When challenged with angiotensin II infusion, adult LP offspring reacted with a greater decline in GFR than controls (80). In another LP study, there were more angiotensin II–positive cells in the cortical tubulointerstitium of adult offspring (82). Offspring from diabetic mothers had marked upregulation of angiotensigen (AGT) and AT1R gene expression as well as increased ACE:ACE2 mRNA ratio (83). Some environmental influences induce RAAS activation already in fetal life. Thus, ovine offspring exposed to high salt during gestation presented with increased gene expression of AGT, ACE, AT1R, and increased ACE:ACE2 and AT1R:AT2R mRNA ratio (78). In the human situation, plasma renin concentrations were elevated in umbilical veins of SGA infants, and birth weight was inversely associated with circulating aldosterone concentrations (84). Treatment of human proximal tubule epithelial cells with palmitic acid demonstrated susceptibility to nutritional factors, as it induced intracellular endoplasmic reticulum (ER) stress and increased angiotensin II concentrations in cell medium. Co-treatment with AT1R-blocker or renin-inhibitor prevented ER stress (85).

**Renal Sodium Transport**

In rats, LP nutrition or dexamethasone treatment during gestation both resulted in an upregulation of the bumetanide-sensitive Na-K-2Cl cotransporter and of the thiazide-sensitive Na-Cl cotransporter in the offspring (86, 87). Adult offspring exposed to LP nutrition during gestation and lactation presented with a reduced diuretic response after a single dose of furosemide (88). After prenatal dexamethasone treatment, proximal tubule Na/H exchanger protein expression was increased, going along with an increase in proximal tubule sodium and volume reabsorption (86, 89). Sodium uptake in renal proximal tubule cells from adult male sheep was enhanced after prenatal betamethasone exposure (90). In rat offspring exposed to experimental utero-placental insufficiency (91) or maternal diabetes (92), sodium-dependent hypertension was observed.

**Vasomotor and Endothelial Function**

Another interesting aspect is the maturation of vascular smooth muscle function and small artery resistance regulation. Sympathectomy suppresses maturation of the gene program involved in small artery resistance regulation (93). Intrauterine and perinatal stress could, therefore, have a major impact on vascular tone regulation. In addition, vasomotor function can be impaired by perinatal hyperoxia (65) and LP diet (94). Endothelial dysfunction has also been described after intrauterine deficiency and may add to hypertension and glomerular damage (95).

**Myogenic Response and Tubuloglomerular Feedback (TGF)**

An impaired myogenic response as well as a disturbed TGF are important contributors to glomerular damage in diabetic and hypertensive nephropathy (96). An altered myogenic response has been described in intrauterine growth-restricted (IUGR) neonates, which may be beneficial postnatally, but harmful in the long run (97). The TGF mechanism matures during fetal life and could, therefore, be susceptible to programming in utero (98).
However, no study has examined the specific consequences of disturbed intrauterine environment for TGF function.

**Epigenetic Mechanisms**

The molecular details of kidney development have been extensively studied (99, 100). Altered DNA methylation, histone modification, and other mechanisms modifying the renal transcriptome may significantly impair renal organogenesis and predispose toward renal disease which has lately been reviewed in detail (101). In this context, it is important to separate epigenetic changes during kidney disease (102) from epigenetic changes during early life leading to “programmed” disease. So far, there is little evidence that single, kidney-specific epigenetic alterations during early life might actually cause renal disease later on. Candidate genes would be all genes which are activated during specific developmental windows. Pax-2, for example, is essential for kidney development, ontogenetically regulated and can be reactivated in repair processes after acute kidney injury (103, 104). Global alterations of methylation associated with hypertension were observed after significant periconceptional deficiency of B vitamins and methionine (105). Thus, nutritional modifications may induce temporary or permanent epigenetic alterations that certainly have the potential to modulate kidney disease.

**Oxidative Stress**

Oxidative stress and inflammation are major contributors to vascular remodeling and hypertension (106). In LP (94, 107) and maternal smoking models (108), it was shown that oxidative stress during critical developmental steps may significantly contribute to renal susceptibility toward disease. In addition, both IUGR offspring after global undernutrition of the dam (109) and after high-fat died during gestation and lactation (110) showed increased oxidative stress and elevated blood pressure later in life. Reduction of oxidative stress during early life might prevent programmed hypertension and renal damage (94, 107, 108).

**Metabolism**

Rapid postnatal weight gain and early life obesity have been associated with adverse renal outcome (111, 112). Interplay between adiposity, leptin, and insulin resistance with RAAS regulation and sympathetic activity has been described (113, 114). Early postnatal overfeeding in rats by litter size reduction induced increased early postnatal weight gain and was associated with increased blood pressure, glomerulosclerosis, and proteinuria in adulthood (71). In a similar study, postnatal overfeeding resulted in decreased GFR, increased proteinuria and increased deposition of collagens. On the molecular level, intrinsic renal leptin resistance could be demonstrated (115). Dysregulation of renal leptin and Akt/AMPKα signaling associated with increased renal matrix deposition could also be shown in overweight offspring from mothers fed a high-fat diet during gestation and lactation (116). Maternal LP nutrition during rat gestation persistently decreased the expression of renal 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) (117, 118) and increased the expression of the renal glucocorticoid receptor in the offspring (118). The same was shown for sheep offspring exposed to temporary maternal calorie restriction (119).

**Arachidonic Acid Metabolism Pathway**

Finally, there is evidence that the arachidonic acid metabolism pathway could be involved in the development of programmed hypertension (120, 121). 20-hydroxyecosatetraenoic acid (20-HETE), a metabolite of arachidonic acid, contributes to the normal myogenic pressure response. Physiologically, arachidonic acid is released from cell membranes by phospholipase A2, converted to 20-HETE, which then adds to vasoconstriction of the afferent arteriole (96, 122). However, 20-HETE has also been linked to systemic hypertension and endothelial dysfunction in rats (123). Further arachidonic acid metabolites like Cox-2 derived prostaglandins contribute to counter regulatory vasodilation of the afferent arteriole after TGF-mediated vasoconstriction (124) and oxidative stress in the kidney (125), and therefore modulate intraglomerular pressure and GFR as well as renal inflammation (82). Thus, nutritional intake of arachidonic acid may significantly affect blood pressure, kidney function, and kidney survival.

**POTENTIAL THERAPEUTIC “REPROGRAMMING” INTERVENTIONS**

The ultimate goal of all research on programmed disease is to develop preventive strategies. So far, the number of studies on re-programming interventions is still limited and mainly restricted to dietary or anti-oxidative approaches.

**Early Dietary Interventions**

Data on nutritional interventions are available from both animal and human studies. A meta-analysis showed slightly, but significantly lower blood pressure in infants, children, and adolescents who were breast fed during infancy compared to those being formula fed (126). Micronutrient (127), calcium (128), vitamin A (129, 130), and iron (131) supplementation during pregnancy as well as long-chain polyunsaturated fatty acid (LCPUFA) supplementation in infant formula (132) may be beneficial to renal outcome.

In detail, children of women receiving a multiple micronutrient supplementation during the second and third trimesters of pregnancy were heavier and had lower systolic blood pressure during infancy (127). Calcium supplementation from the 20th gestational week until delivery lowered systemic blood pressure in children aged 7 years, with a stronger effect when children were overweight (128). Supplementation of iron and folic acid until the end of pregnancy in rural Bangladesh caused a slightly decreased diastolic blood pressure and a slightly increased GFR in infants at the age of 4.5 years when started at the ninth, but not when started at the 20th gestational week (131). Another dietary intervention with micronutrient supplementation in malnourished pregnant Nepalese women until 3 months postpartum showed that folic acid or the combination of folic acid, iron, and zinc reduced the risk of microalbuminuria, but not blood pressure in the children aged 6–8 years (133). The effects of retinoic acid have mainly been studied in animals. Decreased availability of retinoic acid induced by down-regulated vitamin A metabolism after previous overexposure to vitamin A strongly impairs metanephric kidney development, which can be restored by adequate retinoic acid.
supplementation (129). In rat offspring exposed to LP diet of the dam during pregnancy, a single injection of retinoic acid to the dam at midgestation increased postnatal nephron number at 4 weeks of age (130). Postnatal administration of retinoic acid in preterm baboons, however, did not alter kidney growth or nephron number, presumably because the timing of the intervention was chosen too late (134).

Long-chain polyunsaturated fatty acid supplementation with arachidonic acid and docosahexaenoic acid (ratio 2:1) in infant milk formula (IF) during the first 4 months of life lowered blood pressure at 6 years of age compared to IF without LCPUFAs. Blood pressure of children fed LCPUFA-IF was similar compared to breast fed children (132). A diet sufficient in ω-3 PUFAs reduced blood pressure levels compared to a diet almost free of ω-3 PUFAs in TGR (mRen-2)27 rats which have high angiotensin II levels (135). Finally, the importance of the amino acid composition was demonstrated. Addition of glycine to maternal LP diet throughout gestation normalized body weight and blood pressure at 4 weeks of age in rat offspring, whereas alanine or urea had no effect (136).

**Anti-Oxidative Substances**

Re-programming interventions with anti-oxidative substances have only been performed in animals. Supplementation of maternal LP diet with anti-oxidative (ACH09)-derived polyphenols extracted from grape skins reduced signs of renal oxidative stress in the offspring on the first postnatal day and attenuated the adverse effects of maternal LP diet on glomerular number and maturity (107). Administration of a lipid peroxidation inhibitor along with LP diet in gestation reduced prenatal oxidative stress and prevented programming of elevated blood pressure, enhanced vasoconstriction after angiotensin II administration and reduced vasodilation after sodium nitroprusside administration in adult animals (94). Similarly, treatment of previously malnourished dams with α-tocopherol during lactation prevented the development of hypertension in the offspring. In addition, upregulated angiotensin II levels and down-regulated Cox-2 expression in the tubulointerstitium were brought back to control levels and oxidative stress as well as macrophage infiltration was prevented. However, treatment of control dams with α-tocopherol resulted in arterial hypertension of the offspring (82).

**CONCLUSION AND FUTURE DIRECTIONS**

The concept of “developmental origins of health and disease” highlights the interrelationship between environmental factors throughout life and differences in morbidity and mortality between individuals. Chronic kidney disease affects more than 10% of the population (1). High blood pressure, childhood underweight, and suboptimal breastfeeding are among the top risk factors contributing to global burden of disease (137). Prematurity, IUGR, overweight in early life, and other conditions have been associated with the development of arterial hypertension, proteinuria, and decline of renal function. Around 11% of all live-born infants worldwide are born preterm (138). IUGR is seen in 3–7% of all pregnancies (139). During childhood, 5–6% of girls and 7–8% of boys become overweight (140). Thus, renal programming is not a rare phenomenon but affects large parts of the population. Further studies that broaden our understanding of renal programming mechanisms are needed to ultimately develop preventive strategies. Targeted re-programming interventions in animal models focusing on known mechanisms will contribute to new concepts which finally will have to be translated to human application. Early nutritional concepts with specific modifications in macro- or micronutrients are among the most promising approaches to improve future renal health.

**AUTHOR CONTRIBUTIONS**

EN performed the majority of literature research, and designed and wrote the review. K-DN contributed to literature research, and designed and wrote the review. JD and IW contributed to literature research and writing. All authors revised and approved the review.

**REFERENCES**

1. Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet (2013) 382(9887):158–69. doi:10.1016/S0140-6736(13)60439-0
2. Iba V, García-García G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet (2013) 382(9888):260–267. doi:10.1016/S0140-6736(13)60687-X
3. Nüsken E, Nüsken K-D, Dötsch J. Diet and epigenetic alteration of renal function. In: Patel V, Preedy V, editors. Handbook of Nutrition, Diet, and Epigenetics. Cham: Springer International Publishing (2017). p. 1–20.
4. Dötsch J, Alejandro-Alcazar M, Janoschek R, Nüsken E, Weber LT, Nüsken KD. Perinatal programming of renal function. Curr Opin Pediatr (2016) 28(2):188–94. doi:10.1097/MOP.0000000000000332
5. Stritzke A, Thomas S, Amin H, Fisch C, Lodha A. Renal consequences of preterm birth. Mol Cell Pediatr (2017) 4(1):2. doi:10.1186/s40348-016-0068-0
6. Luycx VA. Preterm birth and its impact on renal health. Semin Nephrol (2017) 37(4):311–9. doi:10.1055/s-0043-173536
7. Luycx VA, Brenner BM. Low birth weight, nephron number, and kidney disease. Kidney Int Suppl (2003) 97:S68–77. doi:10.1111/j.1523-1755.2003.009712.x
8. Quigley R. Developmental changes in renal function. Curr Opin Pediatr (2012) 24(2):184–90. doi:10.1097/MOP.0b013e32834fe863
9. Konje JC, Bell SC, Morton JJ, de Chazal R, Taylor DJ. Human fetal kidney morphometry during gestation and the relationship between weight, kidney morphometry and plasma active renin concentration at birth. Clin Sci (Lond) (1996) 91(2):169–75. doi:10.1042/CS9910226
10. Seely JC. A brief review of kidney development, maturation, developmental abnormalities, and drug toxicity: juvenile animal relevancy. J Toxicol Pathol (2017) 30(2):125–33. doi:10.1293/tox.2017-0006
11. Rodríguez MM, Gómez AH, Abitbol CL, Chandar JJ, Duara S, Zilleruelo GE. Histomorphometric analysis of postnatal glomerulogenesis in extremely preterm infants. Pediatr Dev Pathol (2004) 7(1):17–25. doi:10.1016/s10024-003-3029-2
12. Sutherland MR, Gubhaju L, Moore L, Kent AL, Dahlstrom JE, Horne RS, et al. Accelerated maturation and abnormal morphology in the preterm neonatal kidney. J Am Soc Nephrol (2011) 22(7):1363–74. doi:10.1681/ASN.2010121266
13. Aperia A, Broberger O, Herin P, Thodenius K, Zetterström R. Postnatal control of water and electrolyte homeostasis in pre-term and full-term infants. Acta Paediatr Scand Suppl (1983) 305:61–5. doi:10.1111/j.1651-2227.1983.tb09861.x
14. Giniger RP, Buffat C, Millet V, Simeoni U. Renal effects of ibuprofen for the treatment of patent ductus arteriosus in premature infants. J Matern Fetal Neonatal Med (2007) 20(4):275–83. doi:10.1080/14767050701227950.

15. Rhone ET, Carmody JR, Swanson JR, Charlton JR. Nephrotoxic medication exposure in very low birth weight infants. J Matern Fetal Neonatal Med (2014) 27(14):1485–90. doi:10.3109/14767058.2014.860522.

16. Girardi A, Raschi E, Galletti S, Poluzzi E, Faldaella G, Allegaert K, et al. Drug-induced renal damage in preterm neonates: state of the art and methods for early detection. Drug Saf (2015) 38(6):535–51. doi:10.1007/s11704-015-0288-6.

17. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet (2006) 367(9524):1747–57. doi:10.1016/S0140-6736(06)68770-9.

18. Wingen AM, Fabian-Bach C, Schaefer E, Mehli O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet (1997) 349(9059):1117–23. doi:10.1016/S0140-6736(96)08060-4.

19. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med (1996) 334(1):13–8. doi:10.1056/NEJM19960104334010310.

20. Vanhooler R, Massy Z, Argiles A, Spasovski G, Verbeke E, Lameire N, et al. Chronic kidney disease as cause of cardiovascular mortality and mortality. Nephrol Dial Transplant (2005) 20(6):1048–56. doi:10.1093/ndt/gfh813.

21. Schmiede RE. End organ damage in hypertension. Disch Arzctlbl (2010) 107(49):866–73. doi:10.3238/arztebl.2010.0866.

22. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a follow-up study of 50-year-olds. N Engl J Med (1996) 334(1):13–8. doi:10.1056/ NEJM19960104334010310.

23. Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension in apparently healthy children. J Pediatr (2000) 136(1):3–49. doi:10.1159/000457967.

24. Dekkers JC, Snieder H, Van Den Oord EJ, Treiber FA. Moderators of blood pressure 20 years later. J Am Soc Nephrol (2005) 16(10):1472–6. doi:10.1093/ndt/gfh813.

25. Erlingsdottir A, Indridason OS, Thorvaldsson O, Edvardsson VO. Blood pressure and end-stage renal disease. Nephrol Dial Transplant (2001) 16(10):275–83. doi:10.1093/ndt/16.10.275.

26. Edvardsson VO, Steinthorsdottir SD, Eliasdottir SB, Indridason OS, Palsson R. Effect of intrauterine growth retardation on the clinical course and prognosis of IgA glomerulonephritis in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Kidney Int (2006) 367(9524):1747–57. doi:10.1016/j.ijkd.2006.09.013.

27. Becker GJ, Kovesdy CP, Schold JD, Nolph KD. Kidney Failure in Childhood. 5th ed. Springer, Berlin, 2011.

28. Hinchliffe SA, Lynch MR, Sargent PH, Howard CV, Van Velzen D. The effect of intrauterine growth retardation on the development of renal nephrons. Hypertension (1996) 103(3):273–80. doi:10.1161/01.HYP.11.17.5028.1996.b09718.x.

29. Eriksson JG, Forsén TJ, Kajantie E, Osmond C, Barker DJ. Childhood weight and childhood blood pressure. Int J Epidemiol (1996) 25(1):75–9. doi:10.1093/ije/25.1.75.

30. Hallan S, Euser AM, Irgens LM, Finken MJ, Holmen J, Dekker FW. Effect of intrauterine growth restriction on the clinical course and prognosis of IgA glomerulonephritis in children. Nephron (1998) 79(1):28–32. doi:10.1159/ 000044987.

31. Bertram JF, Douglas-Denton RN, Diouf B, Hughson MD, Hoy WE. Human prenatal programming of renal function: the estimated glomerular filtration rate is influenced by size at birth in apparently healthy children. Pediatr Res (2008) 64(1):97–9. doi:10.1203/ PDR.0b013e31817282db.

32. Zidar N, Avgustin Cavić M, Kenda RB, Ferluga D. Effect of intrauterine growth retardation on the clinical course and prognosis of IgA glomerulonephritis in children born small for gestational age. Am J Kidney Dis (2008) 51(6):925–32. doi:10.1053/j.ajkd.2008.12.042.

33. Zidar N, Cavić MA, Kenda RB, Ferluga D. Effect of intrauterine growth retardation on the development of renal nephrons. J Matern Fetal Neonatal Med (2007) 20(4):275–83. doi:10.1080/14767050701227950.

34. Eriksson JG, Forsén TJ, Kajantie E, Osmond C, Barker DJ. Childhood growth and hypertension in later life. Hypertension (2007) 49(6):1415–21. doi:10.1161/HYPERTENSIONAHA.106.085597.

35. Perng-W, Gillman MW, Mantzoros CS, Öken E. A prospective study of maternal prenatal weight and offspring cardiometabolic health in midchildhood. Ann Epidemiol (2014) 24(11):793–800.e1. doi:10.1016/j.annepidem.2014.08.002.

36. Ben-Shlomo Y, McCarthy A, Hughes R, Tilling K, Davies D, Smith GD. Immediate postnatal growth is associated with blood pressure in young adulthood: the Barry Caerphilly Growth Study. Hypertension (2008) 52(4):638–44. doi:10.1161/HYPERTENSIONAHA.108.114256.

37. Hallan S, Euser AM, Irgens LM, Finken MJ, Holmen J, Dekker FW. Effect of intrauterine growth restriction on the clinical course and prognosis of IgA glomerulonephritis in children born small for gestational age. Am J Kidney Dis (2008) 51(6):925–32. doi:10.1053/j.ajkd.2008.12.042.

38. Bertram JF, Douglas-Denton RN, Diouf B, Hughson MD, Hoy WE. Human prenatal programming of renal function: the estimated glomerular filtration rate is influenced by size at birth in apparently healthy children. Pediatr Res (2008) 64(1):97–9. doi:10.1203/ PDR.0b013e31817282db.

39. Hinchliffe SA, Lynch MR, Sargent PH, Howard CV, Van Velzen D. The effect of intrauterine growth retardation on the development of renal nephrons. Br J Obstet Gynaecol (1992) 99(4):296–301. doi:10.1111/j.1471-0528.1992.tb13726.x.
55. Langley-Evans SC, Welham SJ, Jackson AA. Fetal exposure to a maternal low protein diet impairs nephrogenesis and promotes hypertension in the rat. Physiol (1999) 294(2):R543–7. doi:10.1152/physiolrev.1999.89.2.543

56. Jones SE, Bilous RW, Flyvbjerg A, Marshall SM. Intra-uterine environment influences glomerular number and the acute renal adaptation to experimental diabetes. Diabetologia (2001) 44(6):721–8. doi:10.1007/s001250015681

57. Woods LL, Weeks DA, Rasch R. Programming of adult blood pressure by maternal protein restriction: role of nephrogenesis. Kidney Int (2004) 65(4):1339–48. doi:10.1111/j.1523-1755.2004.00511.x

58. Sampogna RV, Schneider L, Al-Awqati Q. Developmental programming of adult blood pressure. Hypertension (2004) 43(6):1283–9. doi:10.1161/01.HYP.0000127787.85259.1F

59. Lisle SJ, Lewis RM, Petry CJ, Ozanne SE, Hales CN, Forhead AJ. Effect of maternal dexamethasone treatment at midgestation reduces nephron number and alters renal gene expression in the fetal spiny mouse. Am J Physiol Regul Integr Comp Physiol (2007) 292(1):R453–61. doi:10.1152/ajpregu.00481.2006

60. Merlet-Bénichou C, Gilbert T, Muffat-Joly M, Lelièvre-Pégorier M, Leroy B. Glomerular number and function are influenced by spontaneous and induced low birth weight in rats. J Am Soc Nephrol (2005) 16(10):2913–9. doi:10.1681/ASN.2004100875

61. Schreuder MF, Nyengaard JR, Fodor M, van Wijk JA, Delemarre-van de Waal HA. Renal molecular mechanisms underlying altered Na+ transport in the adult offspring due to an early impact on local angiotensin II pathways. PLoS One (2011) 6(7):e21232. doi:10.1371/journal.pone.0021232

62. Sanders MW, Fazzi GE, Janssen GM, Blanco CE, De Mey JG. High sodium treatment at midgestation reduces nephron number and alters renal gene expression during kidney development in neonates. Eur J Pediatr (2017) 176(2):183–9. doi:10.1007/s00431-016-2820-9

63. Dickinson H, Walker DW, Wintour EM, Moritz K. Maternal dexamethasone reduces angiotensin II AT(1) and AT(2) receptor expression in the fetal rat kidney. Kidney Blood Press Res (2010) 33(4):251–9. doi:10.1159/000317739

64. Ao Y, Sun Z, Hu S, Zuo N, Li B, Yang S, et al. Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure. Toxicol Appl Pharmacol (2015) 287(2):128–38. doi:10.1016/j.taap.2015.05.007

65. Su Y, Bi J, Pulgar VM, Figueroa J, Chappell M, Rose JC. Antenatal glucocorticoid treatment alters Na+ uptake in renal proximal tubule cells from adult offspring in a sex-specific manner. Am J Physiol Renal Physiol (2015) 308(11):F1268–75. doi:10.1152/ajprenal.00047.2015

66. Vieira-Filho LD, Cabral EV, Farias JS, Silva PA, Muzi-Filho H, Vieyra A, et al. Maternal diabetes programs hypertension and kidney injury in offspring. Diabetes (2014) 63(7):2386–98. doi:10.2337/db13-1506

67. Manning J, Beutler K, Knepper MA, Vehaskari VM. Upregulation of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring. J Am Soc Nephrol (2007) 18(1):61–70. doi:10.1681/ASN.2006070786

68. Edelstein DC, Miller SP, Hales CN, Forhead AJ. Birth weight is inversely associated with blood pressure and serum aldosterone and cortisol levels in children. Clin Endocrinol (Oxf) (2012) 76(5):713–8. doi:10.1111/j.1365-2265.2011.04308.x

69. Su Y, Bi J, Pulgar VM, Figueroa J, Chappell M, Rose JC. Antenatal glucocorticoid treatment alters Na+ uptake in renal proximal tubule cells from adult offspring in a sex-specific manner. Am J Physiol Renal Physiol (2015) 308(11):F1268–75. doi:10.1152/ajprenal.00047.2015

70. Saqib F, Daniel L, Buffat C, Tsimaratos M, Oliver C, et al. Birth weight is inversely associated with blood pressure and serum aldosterone and cortisol levels in children. Clin Endocrinol (Oxf) (2012) 76(5):713–8. doi:10.1111/j.1365-2265.2011.04308.x

71. Tan JC, Workeneh B, Busque S, Blouch K, Derby G, Myers BD. Glomerular function, structure, and number in renal allografts from older deceased donors. J Am Soc Nephrol (2009) 20(1):181–8. doi:10.1681/ASN.2008030306

72. Mühle A, Mühl C, Amann K, Dötsch J, Nüsken KD, Bollte J, et al. No juvenile arterial hypertension in sheep multiples despite reduced nephron numbers. Pediatr Nephrol (2010) 25(9):1653–61. doi:10.1007/s00467-010-1512-3

73. Bozbeyli Y, Sarsoglu M, Gökçeçay M, Aydinli U, Saka F, et al. Maternal hypertension in the offspring of spontaneously hypertensive rats is associated with decreased number of nephrons. Pediatr Nephrol (2011) 26(10):2023–8. doi:10.1007/s00467-011-1823-6

74. Stoltz C, Allen KP, Mattson DL, Lerch-Gaggl A, Reddy S, El-Meanawy A. Prematurity in mice leads to reduction in nephron number, hypertension, and proteinuria. Transl Res (2012) 159(2):80–9. doi:10.1016/j.trsl.2011.10.004

75. Kannel WB, Sorlie P, Feinleib M, Verter A, Kagan A. Hypertension in the elderly: the Framingham study. Am J Epidemiol (1971) 93(2):148–67. doi:10.1093/oxfordjournals.aje.a118880

76. Tijet N, Sturkenboom C, Geenen T, van der Zee E, Rozendaal N, et al. Maternal diabetes programs hypertension and kidney injury in offspring. Pediatr Nephrol (2010) 25(7):1319–29. doi:10.1007/s00467-010-1506-1

77. Ao Y, Sun Z, Hu S, Zuo N, Li B, Yang S, et al. Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure. Toxicol Appl Pharmacol (2015) 287(2):128–38. doi:10.1016/j.taap.2015.05.007

78. Reho JJ, Zheng X, Benjamin JE, Fisher SA. Neural programming of mesenteric and renal arteries. Am J Physiol Heart Circ Physiol (2014) 307(5):H563–73. doi:10.1152/ajpheart.00259.2014
103. Soofi A, Levitan I, Dressler GR. Two novel EGFP insertion alleles reveal
104. Imgrund M, Gröne E, Gröne HJ, Kretzler M, Holzman L, Schlöndorff D,
101. Dressler GR, Patel SR. Epigenetics in kidney development and renal disease.
100. Kuure S, Vuolteenaho R, Vainio S. Kidney morphogenesis: cellular
112. Wang Y, Chen X, Klag MJ, Caballero B. Epidemic of childhood obesity:
111. Yim HE, Yoo KH. Early life obesity and chronic kidney disease in later life.
109. Rodríguez-Rodríguez P, de Pablo AL, Condezo-Hoyos L, Martín-
107. Costa MR, Pires KM, Nalbones-Barbosa MN, Dos Santos Valença S,
96. Burke M, Pabbidi MR, Farley J, Roman RJ. Molecular mechanisms of renal
99. Rumballe B, Georgas K, Wilkinson L, Little M. Molecular anatomy of the
98. Brown RD, Turner AJ, Carlström M, Persson AE, Gibson KJ. Tubuloglomerular
90. Kuure S, Vuolteenaho R, Vainio S. Kidney morphogenesis: cellular and
91. Wang Y, Chen X, Klag MJ, Caballero B. Epidemic of childhood obesity: effects of maternal B vitamin status on fetal and offspring development in a low-protein rat model of intrauterine growth restriction. *Proc Natl Acad Sci U S A* (2007) 104(49):19351–6. doi:10.1073/pnas.0707258104
90. Guxti T, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension. *Hypertension* (2017) 70(4):660–7. doi:10.1161/HYPERTENSIONAHA.117.1175802
107. Costa MR, Pires KM, Nalbones-Barbosa MN, Dos Santos Valença S, Resende AC, de Moura RS. Grape skin extract-derived polyphenols modify muscle fiber-type distribution and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. *Physiol Rep* (2015) 3:13064. doi:10.14814/phy2.13064
108. Stangenberg S, Nguyen LT, Chen H, Al-Odat I, Killingsworth MC, Gosnell ME, et al. Oxidative stress, mitochondrial perturbations and fetal programming of renal disease induced by maternal smoking. *Int J Biochem Cell Biol* (2015) 64:81–90. doi:10.1016/j.biocel.2015.03.017
109. Rodríguez-Rodríguez P, de Pablo AL, Condezo-Hoyos L, Martín-Cabrejas MA, Aguilera Y, Ruiz-Hurtado G, et al. Fetal undernutrition is associated with perinatal sex-dependent alterations in oxidative status. *J Nutr Biochem* (2015) 26(12):1650–9. doi:10.1016/j.jnutbio.2015.08.004
110. Tain YL, Lin YJ, Sheen JM, Yu HR, Tiao MM, Chen CC, et al. High fat diets sex-specifically affect the renal transcriptome and program obesity, kidney injury, and hypertension in the offspring. *Nutrients* (2017) 9(4):E4357. doi:10.3390/nu90404357
111. Yim HE, Yoo KH. Early life obesity and chronic kidney disease in later life. *Pediatr Nephrol* (2015) 30(8):1255–63. doi:10.1007/s00467-014-3192-4
112. Wang Y, Chen X, Klag MJ, Caballero B. Epidemic of childhood obesity: implications for kidney disease. *Adv Chronic Kidney Dis* (2006) 13(4):336–51. doi:10.1016/j.ackd.2006.07.016
113. Manrique C, Lastra G, Gardner M, Sowers JR. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. *Med Clin North Am* (2009) 93(3):569–82. doi:10.1016/j.mcna.2009.02.014
132. Forsyth JS, Willatts P, Agostoni C, Bissenden J, Csaaper P, Boehm G. Long chain polyunsaturated fatty acid supplementation in infant formula and blood pressure in later childhood: follow up of a randomised controlled trial. BMJ (2003) 326(7396):953. doi:10.1136/bmj.326.7396.953

133. Stewart CP, Christian P, Schulze KJ, West KP Jr, Khayry SK. Antenatal micronutrient supplementation reduces metabolic syndrome in 6- to 8-year-old children in rural Nepal. J Nutr (2009) 139(8):1575–81. doi:10.3945/jn.109.106666

134. Sutherland MR, Gubhaju L, Yoder BA, Stahlman MT, Black MJ. The effects of postnatal retinoic acid administration on nephron endowment in the preterm baboon kidney. Pediatr Res (2009) 65(4):397–402. doi:10.1203/PDR.0b013e3181975f52

135. Jayasooriya AP, Begg DP, Chen N, Mathai ML, Sinclair AJ, Wilkinson-Berka J, et al. Omega-3 polyunsaturated fatty acid supplementation reduces hypertension in TGR(mRen-2)27 rats. Prostaglandins Leukot Essent Fatty Acids (2008) 78(1):67–72. doi:10.1016/j.plefa.2007.11.001

136. Jackson AA, Dunn RL, Marchand MC, Langley-Evans SC. Increased systolic blood pressure in rats induced by a maternal low-protein diet is reversed by dietary supplementation with glycine. Clin Sci (Lond) (2002) 103(6):633–9. doi:10.1042/cs1030633

137. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease study 2010. Lancet (2012) 380(9859):2224–60. doi:10.1016/S0140-6736(12)61766-8

138. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet (2012) 379(9832):2162–72. doi:10.1016/S0140-6736(12)60820-4

139. Romo A, Carceller R, Tobajas J. Intrauterine growth retardation (IUGR): epidemiology and etiology. Pediatr Endocrinol Rev (2009) 6(Suppl 3):332–6.

140. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet (2017) 390(10113):2627–42. doi:10.1016/S0140-6736(17)32293-9

Conflict of Interest Statement: The authors declare that the article was written in absence of any commercial or financial relationships that could be a potential conflict of interest to the topic.

Copyright © 2018 Nüsken, Dötsch, Weber and Nüsken. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.